Drugs in Dev. Neurology
Phase IV
United States 
Lead Product(s) : Valbenazine Tosylate
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurocrine Reports INGREZZA Improves TD Function & QoL
Details : Ingrezza (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for the treatment adults with tardive dyskinesia.
Product Name : Ingrezza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : Valbenazine Tosylate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Details : Ajovy (fremanezumab) is a FDA approved, humanized monoclonal antibody which selectively binds the calcitonin gene-related peptide, it is indicated for preventive treatment of migraine in adults.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.
Product Name : Elyxyb
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ajovy (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AJOVY (Fremanezumab-vfrm) is a subcutaneous injection of the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. it's used for patients with chronic and episodic migraine.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
June 30, 2023
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anjeso (meloxicam) injection, a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities, which are believed to be related to the inhibition of COX-2 and subsequent reduction in prostaglandin biosynthesis.
Product Name : Anjeso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) Tablets is first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by U.S. Food and Drug Administration in adults for treatment of tardive dyskinesia and for treatment of chorea associated with Huntington’...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Details : The confirmatory ENVISION trial is a requirement based on FDA’s accelerated approval of ADUHELM® (aducanumab-avwa), a monoclonal antibody directed against amyloid beta, 100 mg/mL injection for intravenous use in early Alzheimer’s disease.
Product Name : Aduhelm
Product Type : Antibody
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New real-world data show MAVENCLAD® (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.
Product Name : Mavenclad
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 24, 2022
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Details : ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Product Name : Aduhelm
Product Type : Antibody
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
